Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTSultan KhalidSat, June 27, 2026 at 6:14 AM GMT+2 2 min readWith an annual dividend yield of 5.79%, Sanofi (NASDAQ:SNY) is included among the 12 Best NASDAQ Stocks to Buy for Dividends.BofA Expects Positive Investor Reaction to Leadership Update at Sanofi (SNY)Sanofi (NASDAQ:SNY) is a healthcare biopharmaceutical company that engages in the research, development, manufacture, and marketing of therapeutic solutions.Sanofi (NASDAQ:SNY) announced on June 22 that it was appointing Dr Paulo Fontoura as its new Executive Vice President, Global Head of Research & Development Pharma. Dr. Fontoura will replace Dr. Houman Ashrafian and will take charge of his new role on September 1. As head of R&D pharma, he will oversee the company's research, translational medicine, clinical development, and regulatory affairs arms, driving innovation while focusing on advancing a differentiated pipeline and accelerating the delivery of medicines.Following the announcement, BofA analyst Sachin Jain stated that the leadership change is likely to be viewed favorably by investors, given Sanofi's recent series of setbacks in R&D. However, the analyst highlighted Dr. Fontoura's "mixed track record" from his time at Roche and noted that his new role will likely be a multi-year project to revitalize Sanofi's R&D organization.Bofa maintains a 'Neutral' rating and €92 price target on Sanofi (NASDAQ:SNY), implying an upside of almost 25% from the current levels.While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.READ NEXT: 12 Best S&P 500 Stocks to Buy for Dividends and 12 High Yield Fortune 500 Stocks to Buy NowDisclosure: None. Follow Insider Monkey on Google News.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info